Table 3.
Multivariate Analysis of the Associations Between Prognostic Value and Disease-Free and Overall Survival Rates in Patients with Early-Stage Cervical Adenocarcinoma
| Variable | Disease-Free Survival | Overall Survival | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| FIGO stage | 2.714 | 1.051–7.011 | 0.039* | 1.357 | 0.343–5.369 | 0.664 |
| Differentiation | 3.841 | 1.498–9.849 | 0.005* | 3.279 | 1.200–8.957 | 0.021* |
| Myometrial invasion | 4.846 | 1.680–13.983 | 0.004* | 4.853 | 1.718–13.712 | 0.003* |
| Parametrial extension | 1.208 | 0.181–8.056 | 0.845 | 3.41 | 0.423–27.488 | 0.249 |
| Endometrial extension | 1.541 | 0.427–5.568 | 0.509 | 0.705 | 0.139–3.582 | 0.674 |
| CA125 | 1.412 | 0.300–6.646 | 0.662 | - | - | - |
| CEA | 0.915 | 0.189–4.428 | 0.912 | 0.841 | 0.167–4.223 | 0.833 |
| Combination of CA125 and CEA | 3.325 | 1.048–10.550 | 0.041* | 5.152 | 1.653–16.055 | 0.005* |
Note: *Significant differences (P < 0.05) of the associations between prognostic value and disease-free and overall survival rates in patients with early-stage cervical adenocarcinoma.
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; 95% CI, 95% confidence interval.